(Q37867481)

24 August 2017

1 reference

title

Pharmacogenetic testing: time for clinical practice guidelines (English)

1 reference

24 August 2017

U Amstutz

1

1 reference

24 August 2017

B C Carleton

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

20 April 2011

1 reference

Clinical Pharmacology & Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

89

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

924-927

1 reference

Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

"Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Drug interactions and pharmacogenomics in the treatment of breast cancer and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Update of the BIG 1-98 Trial: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Guidelines for prescribing azathioprine in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

Tamoxifen in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacogenetics: From Bench to Byte

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

inferred from DOI database lookup

7 January 2021

based on heuristic

What is clinical utility and why should we care?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.18

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.18

1 reference

Dimensions Publication ID

24 August 2017

1042927674

0 references

1 reference